Atlas Trials

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

Clinical trial NCT01728207 · TERMINATED

Trial details

NCT number
NCT01728207
Sponsor
Gilead Sciences
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Non-hodgkin's LymphomaFollicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Start date
2013-03-01
Primary completion
2017-03-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.